Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Status:
Completed
Trial end date:
2009-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to investigate whether or not maribavir is safe and
effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who
have had a stem cell transplant.